RxDoctor Payments Data

Justus Thomas, MD

Ophthalmology · Kingwood, TXNPI 1316051907

Payments from drug & device makers

$14,424in general payments, 2019–2025

Across 367 payments — averaging $39.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Alcon$3K
  • Carl Zeiss Meditec, Inc.$846
  • Bausch Health US, LLC$687
  • Oyster Point Pharma, Inc.$604
  • Bausch & Lomb Americas Inc.$569
  • plus $3K from 21 others

What the payments were for

  • Consulting fees$3,12523%
  • Travel & lodging$7505%
  • Food & beverage$9,82772%
  • Gifts$360%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,424 in reported general payments places this provider in the 85th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$468,265
Medicare patients
1,309
Services billed
3,503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine573$617,591
Cyclosporine228$117,084
LumiganBimatoprost204$100,513
XiidraLifitegrast82$89,973
XdemvyLotilaner33$59,130
TyrvayaVarenicline Tartrate41$27,482
Prednisolone Acetate649$27,378
MieboPerfluorohexyloctane/Pf29$26,972
CequaCyclosporine26$23,094
MoxifloxacinMoxifloxacin Hcl823$17,380
Loteprednol Etabonate63$11,138
Alphagan PBrimonidine Tartrate17$10,698
Ketorolac Tromethamine646$8,974
CombiganBrimonidine Tartrate/Timolol18$8,469
Tobradex StTobramycin/Dexamethasone26$6,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$5,322$737,272812 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$569$116,945111 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$163$59,13033 claims
Oyster Point Pharma, Inc.Tyrvaya$604$27,48241 claims
Sun Pharmaceutical Industries Inc.Cequa$227$23,09426 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm, Besivance$378$17,97092 claims
Eyevance Pharmaceuticals LLCTobradex St, Flarex$41$7,39337 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Kingwood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →